FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892214336> ?p ?o ?g. }

• W2892214336 endingPage "e14034" @default.
• W2892214336 startingPage "e14034" @default.
• W2892214336 abstract "e14034 Background: MYL-1402O is a proposed bevacizumab biosimilar. The similarity of MYL-1402O to Avastin has been demonstrated in physicochemical analyses, and nonclinical studies. Methods: This single-center, randomized, double blind, three-arm, parallel-group, study was conducted in healthy adult male volunteers. The primary objective of this study was to establish PK similarity of A to B and C, and B to C. Subjects were randomized to receive either A, B or C 1 mg/kg over 90 minutes as an intravenous infusion. Dose was selected based on the lower dose in the linear range of PK and acceptable safety in healthy volunteers. Bioequivalence was to be concluded if the 90% CIs of the ratios (A/B, A/C and B/C) of LS means of the natural log transformed AUC 0-inf were within 80% to 125%. AUC 0-t , C max , t max , kel and t½ were assessed as secondary PK parameters. Results: A total of 111 subjects (37/treatment) were enrolled and 110 [37 (A), 36 (B), 37(C)] were included in the analysis. Bioequivalence was demonstrated between A and B, A and C and between B and C. LS mean ratios were close to 1, and 90% CIs were within 0.80 to 1.25 for all of the comparisons. The secondary PK parameters were also comparable with the 90% CIs for ratios of AUC 0-t and C max within 80%-125%. A total of 313 TEAEs were reported, 116 by 33 (89%) subjects who received A, 99 by 29 (78%) subjects who received B and 98 by 28 (76%) subjects who received C. Most TEAEs were consistent with the clinical data of bevacizumab (Avastin). No serious or unexpected TEAEs were reported. TEAEs were grade 1 or grade 2 in severity. The anti-drug antibodies are being evaluated (pending results). Conclusions: These results confirm bioequivalence of Myl-1402O vs. EU-Avastin and US-Avastin. All treatments were well tolerated and no significant safety issues emerged. Clinical trial information: NCT02469987 Clinical trial information: NCT02469987." @default.
• W2892214336 created "2018-09-27" @default.
• W2892214336 creator A5001664839 @default.
• W2892214336 creator A5002879591 @default.
• W2892214336 creator A5020953670 @default.
• W2892214336 creator A5031417366 @default.
• W2892214336 creator A5060408011 @default.
• W2892214336 creator A5075086019 @default.
• W2892214336 creator A5075175180 @default.
• W2892214336 creator A5078629724 @default.
• W2892214336 creator A5082560000 @default.
• W2892214336 date "2017-05-20" @default.
• W2892214336 modified "2023-09-27" @default.
• W2892214336 title "A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C)." @default.
• W2892214336 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14034" @default.
• W2892214336 hasPublicationYear "2017" @default.
• W2892214336 type Work @default.
• W2892214336 sameAs 2892214336 @default.
• W2892214336 citedByCount "4" @default.
• W2892214336 countsByYear W28922143362021 @default.
• W2892214336 crossrefType "journal-article" @default.
• W2892214336 hasAuthorship W2892214336A5001664839 @default.
• W2892214336 hasAuthorship W2892214336A5002879591 @default.
• W2892214336 hasAuthorship W2892214336A5020953670 @default.
• W2892214336 hasAuthorship W2892214336A5031417366 @default.
• W2892214336 hasAuthorship W2892214336A5060408011 @default.
• W2892214336 hasAuthorship W2892214336A5075086019 @default.
• W2892214336 hasAuthorship W2892214336A5075175180 @default.
• W2892214336 hasAuthorship W2892214336A5078629724 @default.
• W2892214336 hasAuthorship W2892214336A5082560000 @default.
• W2892214336 hasConcept C112705442 @default.
• W2892214336 hasConcept C126322002 @default.
• W2892214336 hasConcept C126894567 @default.
• W2892214336 hasConcept C168563851 @default.
• W2892214336 hasConcept C197934379 @default.
• W2892214336 hasConcept C2776694085 @default.
• W2892214336 hasConcept C2777802072 @default.
• W2892214336 hasConcept C42404028 @default.
• W2892214336 hasConcept C59491497 @default.
• W2892214336 hasConcept C71924100 @default.
• W2892214336 hasConcept C90924648 @default.
• W2892214336 hasConcept C98274493 @default.
• W2892214336 hasConceptScore W2892214336C112705442 @default.
• W2892214336 hasConceptScore W2892214336C126322002 @default.
• W2892214336 hasConceptScore W2892214336C126894567 @default.
• W2892214336 hasConceptScore W2892214336C168563851 @default.
• W2892214336 hasConceptScore W2892214336C197934379 @default.
• W2892214336 hasConceptScore W2892214336C2776694085 @default.
• W2892214336 hasConceptScore W2892214336C2777802072 @default.
• W2892214336 hasConceptScore W2892214336C42404028 @default.
• W2892214336 hasConceptScore W2892214336C59491497 @default.
• W2892214336 hasConceptScore W2892214336C71924100 @default.
• W2892214336 hasConceptScore W2892214336C90924648 @default.
• W2892214336 hasConceptScore W2892214336C98274493 @default.
• W2892214336 hasIssue "15_suppl" @default.
• W2892214336 hasLocation W28922143361 @default.
• W2892214336 hasOpenAccess W2892214336 @default.
• W2892214336 hasPrimaryLocation W28922143361 @default.
• W2892214336 hasRelatedWork W1553637968 @default.
• W2892214336 hasRelatedWork W2008610508 @default.
• W2892214336 hasRelatedWork W2017999632 @default.
• W2892214336 hasRelatedWork W2369726129 @default.
• W2892214336 hasRelatedWork W2883744750 @default.
• W2892214336 hasRelatedWork W3089081291 @default.
• W2892214336 hasRelatedWork W3124395146 @default.
• W2892214336 hasRelatedWork W4233707738 @default.
• W2892214336 hasRelatedWork W4291033701 @default.
• W2892214336 hasRelatedWork W4296964712 @default.
• W2892214336 hasVolume "35" @default.
• W2892214336 isParatext "false" @default.
• W2892214336 isRetracted "false" @default.
• W2892214336 magId "2892214336" @default.
• W2892214336 workType "article" @default.